Sagimet Biosciences
IPOAdvancing FASN Inhibitors for Metabolic Disease
Public · San Mateo, United States · Founded 2006 · $153.5M raised
- Headquarters
- San Mateo, California
- Employees
- 11–50
- Founded
- 2006
- Business Model
- B2B
- Website
- sagimet.com
- Total Funding
- $153.5M
- Last Round
- $80.0M Growth EquityFeb 2021
- Rounds
- 4
- Type
- Public
About
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors. Lead candidate denifanstat is an oral, once-daily selective FASN inhibitor in Phase 3 for MASH. FDA Breakthrough Therapy designation. HQ San Mateo. Nasdaq: SGMT.
Summary
Sagimet Biosciences is a Biotech company based in San Mateo, United States, founded in 2006. It has raised $153.5M in total across 4 rounds, most recently a $80.0M Growth Equity round in Feb 2021. Investors include Ascletis, Kleiner Perkins and New Enterprise Associates.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2023
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...